<DOC>
	<DOCNO>NCT00663741</DOCNO>
	<brief_summary>This study investigate safety , pharmacokinetics preliminary efficacy profile sorafenib combination S-1 plus cisplatin Asian patient unresectable / recurrent gastric cancer .</brief_summary>
	<brief_title>Sorafenib Gastric Cancer Asian Phase I Study</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological cytological confirmation primary unresectable recurrent gastric cancer ( without measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) allow ) . Peritoneal dissemination without ascites allow . No prior systemic anticancer therapy include chemotherapy , immunotherapy , target agent experimental therapy advance disease Prior adjuvant therapy/neo adjuvant therapy allow recurrence occur 6 month completion therapy Age &gt; /= 18 year &lt; 75 year Known brain metastasis , spinal cord compression meningeal carcinomatosis . Clinically relevant ascites Concurrent cancer distinct primary site histology gastric cancer Any condition impair patient 's ability swallow whole pill</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Unresectable / recurrent gastric cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>S-1</keyword>
	<keyword>Gastric</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>CDDP</keyword>
</DOC>